Sale of Priority Review Voucher	9 Months Ended
Sep. 30, 2026
Discontinued Operations and Disposal Groups [Abstract]
Sale of Priority Review Voucher	Sale of Priority Review Voucher In June 2026, the Company entered into an asset purchase agreement (the "PRV Transfer Agreement") for the sale of its rare pediatric disease priority review voucher ("PRV") for gross proceeds of $195.0 million in cash. The Company received the PRV in connection with the FDA accelerated approval of AVLAYAH in March 2026. In July 2026, the Company completed the sale and received net proceeds of $194.0 million after deducting transaction costs paid at closing. These net proceeds were recognized as a gain, presented separately within Other income in the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2026.

Sale of Priority Review Voucher

9 Months Ended

Sep. 30, 2026

Discontinued Operations and Disposal Groups [Abstract]

In June 2026, the Company entered into an asset purchase agreement (the "PRV Transfer Agreement") for the sale of its rare pediatric disease priority review voucher ("PRV") for gross proceeds of $195.0 million in cash. The Company received the PRV in connection with the FDA accelerated approval of AVLAYAH in March 2026.

In July 2026, the Company completed the sale and received net proceeds of $194.0 million after deducting transaction costs paid at closing. These net proceeds were recognized as a gain, presented separately within Other income in the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2026.